Patients with metastatic clear cell renal carcinoma BrM treated with SRS and stratified by changing or continuing systemic treatment (VEGFR tyrosine kinase inhibitors, mTOR inhibitors, immune checkpoint, or other therapies). The gene discussed is MTOR; the disease is clear cell renal carcinoma.